Loading...

APC anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1dot2_APC_032808
PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
  • XMG1dot2_APC_032808
    PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
505809 25 µg 44 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505810 100 µg 132 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  2. Tian WJ, et al. 2021. Clin Exp Pharmacol Physiol. 48:902. PubMed
  3. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  4. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  5. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  6. Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed
  7. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
  8. Qu L, et al. 2022. Cell. 185:1728. PubMed
  9. Grebinoski S, et al. 2022. Nat Immunol. 23:868. PubMed
  10. Guo X, et al. 2022. Invest Ophthalmol Vis Sci. 63:12. PubMed
  11. Blanas A, et al. 2022. iScience. 25:104719. PubMed
  12. Gary EN, et al. 2022. Cell Rep Med. 3:100693. PubMed
  13. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  14. Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed
  15. Balood M, et al. 2022. Nature. 611:405. PubMed
  16. Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed
  17. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  18. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  19. Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed
  20. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  21. Phares TW, et al. 2022. Front Pharmacol. 13:1029636. PubMed
  22. Xiao J, et al. 2023. J Clin Invest. 133: . PubMed
  23. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  24. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  25. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  26. Vijver SV, et al. 2023. Front Immunol. 13:1100730. PubMed
  27. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  28. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  29. Tao X, et al. 2022. J Exp Med. 219:. PubMed
  30. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  31. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  32. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  33. Wang Z, et al. 2022. J Control Release. 349:929. PubMed
  34. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  35. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  36. Shi X, et al. 2023. iScience. 26:106143. PubMed
  37. Tursi NJ, et al. 2023. Front Immunol. 14:1072810. PubMed
  38. Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed
  39. Latour YL, et al. 2023. Gut Microbes. 15:2192623. PubMed
  40. Mackin S, et al. 2023. Nat Microbiol. 8:569. PubMed
  41. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  42. Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed
  43. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  44. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  45. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  46. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  47. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  48. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  49. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  50. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  51. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  52. Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed
  53. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  54. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  55. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  56. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  57. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  58. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
  59. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  60. Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed
  61. Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed
  62. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  63. Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
  64. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  65. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  66. Suresh R, et al. 2020. J Immunother Cancer. 8:. PubMed
  67. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  68. Laroche-Lefebvre C, et al. 2016. J Immunol. 197: 3618 - 3627. PubMed
  69. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
  70. Yang C, et al. 2018. J Immunol. 200:1316. PubMed
  71. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  72. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  73. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  74. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  75. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  76. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  77. Zhao Y, et al. 2015. PLoS One. 10: 0134797. PubMed
  78. Diao L, et al. 2022. iScience. 25:105511. PubMed
  79. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  80. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  81. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  82. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  83. Lu J, et al. 2018. ACS Nano. 12:11041. PubMed
  84. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  85. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  86. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  87. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  88. Guo Q, et al. 2021. Front Cardiovasc Med. 8:633212. PubMed
  89. Gu M, et al. 2021. Nat Immunol. 22:193. PubMed
  90. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  91. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  92. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  93. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  94. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  95. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  96. Saini V, et al. 2020. Nat Commun. 0.845138889. PubMed
  97. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  98. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  99. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  100. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  101. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  102. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  103. Konrath KM, et al. 2022. Cell Rep. 38:110318. PubMed
  104. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  105. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  106. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  107. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  108. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  109. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  110. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  111. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  112. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  113. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  114. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  115. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  116. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  117. Lai C, et al. 2009. Invest Ophthalmol Vis Sci. 50:4279. PubMed
  118. Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed
  119. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  120. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  121. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  122. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  123. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  124. Mills C, et al. 2022. Cells. 11:. PubMed
  125. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  126. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  127. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  128. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  129. Harty J 2009. Infect Immun. 77:1894. PubMed
  130. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  131. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  132. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  133. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  134. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  135. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  136. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  137. Marks KE, et al. 2021. Cell Reports. 35(13):109303. PubMed
  138. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  139. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  140. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  141. Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed
  142. El-Zaatari M, et al. 2014. J Immunol. 193:807. PubMed
  143. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  144. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
  145. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  146. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  147. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  148. Souza COS, et al. 2021. iScience. 24(6):102548. PubMed
  149. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  150. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  151. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  152. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  153. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  154. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  155. Park JY, et al. 2019. Cell Rep. 27:2548. PubMed
  156. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  157. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  158. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  159. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  160. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  161. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  162. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  163. Baban B, et al. 2021. JCI Insight. 6:00. PubMed
  164. Yong L, et al. 2022. Nat Commun. 13:4255. PubMed
  165. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  166. Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed
  167. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  168. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  169. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  170. Levesque S, et al. 2019. Oncoimmunology. 8:e1657375. PubMed
  171. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  172. Huang F, et al. 2018. Oncoimmunology. 7:e1450713. PubMed
  173. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  174. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  175. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  176. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  177. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  178. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  179. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  180. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  181. Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed
  182. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  183. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  184. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  185. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  186. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
  187. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  188. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  189. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  190. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  191. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  192. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  193. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  194. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  195. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  196. Pandit M, et al. 2021. Eur J Immunol. 51:1461. PubMed
  197. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  198. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  199. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  200. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  201. Jin R, et al. 2008. J Immunol. 180:2256. PubMed
  202. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  203. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  204. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  205. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  206. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  207. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  208. Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed
  209. Derada Troletti C, et al. 2021. Cell Reports. 35(9):109201. PubMed
  210. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  211. Gupta S, et al. 2022. Life Sci. 288:120182. PubMed
  212. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  213. M H, et al. 2016. Open Bio. 6: 150208. PubMed
  214. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  215. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  216. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  217. Moon J, et al. 2020. Immune Netw. 20:e40. PubMed
  218. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  219. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  220. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  221. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  222. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  223. Li E, et al. 2021. Front Immunol. 12:667177. PubMed
  224. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  225. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  226. Kurihara T, et al. 2015. PLoS One. 10: e0139692. PubMed
  227. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  228. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  229. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  230. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  231. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  232. Byrne K, et al. 2014. J Immunol. 192:1433. PubMed
  233. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  234. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  235. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed
  236. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  237. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  238. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  239. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  240. Okuyama Y, et al. 2020. FASEB J. 540:34. PubMed
  241. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  242. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  243. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  244. Bransi A, et al. 2015. Cancer Immunol Res. 3: 1279 - 1288. PubMed
  245. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  246. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  247. Kwak JE, et al. 2019. Nat Commun. 10:3836. PubMed
  248. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  249. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  250. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  251. Yang N, et al. 2021. NPJ Precis Oncol. 5:37. PubMed
  252. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  253. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  254. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  255. Sheng J, et al. 2021. eLife. 10:00. PubMed
  256. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  257. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  258. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  259. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  260. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  261. Yang L, et al. 2021. Front Immunol. 12:722273. PubMed
  262. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  263. Tang L, et al. 2022. Front Immunol. 12:770402. PubMed
  264. Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
  265. Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed
  266. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  267. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  268. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  269. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  270. Kalim KW, et al. 2021. Front Immunol. 12:726393. PubMed
RRID
AB_315403 (BioLegend Cat. No. 505809)
AB_315404 (BioLegend Cat. No. 505810)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All IFN-γ Reagents Request Custom Conjugation
Description Clone Applications
Alexa Fluor® 700 anti-mouse IFN-γ XMG1.2 ICFC
APC/Cyanine7 anti-mouse IFN-γ XMG1.2 ICFC
GoInVivo™ Purified anti-mouse IFN-γ XMG1.2 ELISA Capture,ELISPOT Capture,CyTOF®,Neut,ICFC,IHC,WB
APC/Fire™ 750 anti-mouse IFN-γ XMG1.2 ICFC
APC anti-mouse IFN-γ XMG1.2 ICFC
Biotin anti-mouse IFN-γ XMG1.2 ELISA Detection,ELISPOT Detection,ICFC
FITC anti-mouse IFN-γ XMG1.2 ICFC
PE anti-mouse IFN-γ XMG1.2 ICFC
Purified anti-mouse IFN-γ XMG1.2 ELISA Capture,CyTOF®,IHC,WB
Alexa Fluor® 488 anti-mouse IFN-γ XMG1.2 ICFC
Alexa Fluor® 647 anti-mouse IFN-γ XMG1.2 ICFC
Pacific Blue™ anti-mouse IFN-γ XMG1.2 ICFC
PerCP/Cyanine5.5 anti-mouse IFN-γ XMG1.2 ICFC
PE/Cyanine7 anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 421™ anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 650™ anti-mouse IFN-γ XMG1.2 ICFC
Ultra-LEAF™ Purified anti-mouse IFN-γ XMG1.2 ELISA Capture,ELISPOT Capture,CyTOF®,Neut,ICFC,IHC,WB
Brilliant Violet 711™ anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 785™ anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 605™ anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 510™ anti-mouse IFN-γ XMG1.2 ICFC
PE/Dazzle™ 594 anti-mouse IFN-γ XMG1.2 ICFC
Purified anti-mouse IFN-γ (Maxpar® Ready) XMG1.2 ELISA Capture,CyTOF®
Spark NIR™ 685 anti-mouse IFN-γ XMG1.2 ICFC
Spark UV™ 387 anti-mouse IFN-γ XMG1.2 ICFC
Brilliant Violet 750™ anti-mouse IFN-γ XMG1.2 ICFC
TotalSeq™-C1526 anti-mouse IFN-γ Antibody XMG1.2 ICPG
Spark PLUS UV395™ anti-mouse IFN-γ XMG1.2 ICFC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account